Hyderabad: Amid vaccine scarcity, Indian vaccine manufacturer Bharat Biotech on Thursday announced additional manufacturing capacity at Chiron Behrin Vaccines, Ankaleswar, Gujarat, a wholly owned subsidiary of the company.
The additional capacity will enable Bharat Biotech to ramp up its Covaxin manufacturing capacity by 200 million per annum.
“ The Company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology under stringent levels of GMP and biosafety. Production availability at the Ankaleswar to commence from Q4 of 2021” said Bharat Biotech.
“Bharat Biotech has already deployed multiple production lines at its Hyderabad and Bengaluru campuses. Adding Chiron Behring facility to this line up of high containment SSL fated GMP Facilities that are required to manufacture COVAXIN. This effectively takes the volumes upto -1 Billion doses per annum, with its own established campuses specialized for manufacturing inactivated viral vaccines under the highest levels of bio safety” it added.